Metformin / LDH Cancer Research Results

MET, Metformin: Click to Expand ⟱
Features: oral antidiabetic agent,
Metformin is a pleiotropic drug: attributed to its action on AMPK
Metformin is a biguanide drug used primarily for type 2 diabetes. Mechanistically, it is best described as a bioenergetic modulator: partial inhibition of mitochondrial respiration can raise AMP/ADP, engage AMPK, and suppress mTORC1 signaling; systemically it reduces hepatic gluconeogenesis and can lower insulin/IGF-1 growth signaling. In oncology, observational studies suggested improved outcomes in some settings, but randomized trial data are mixed (e.g., large adjuvant breast cancer data did not show broad benefit overall). Long-term use can be associated with vitamin B12 deficiency, and prescribing requires attention to renal function due to rare lactic acidosis risk in predisposed states.
Metformin directly(partially) inhibits Complex I of the electron transport chain (ETC) in mitochondria. This inhibition decreases mitochondrial ATP production and forces cells to rely more on glycolysis for energy.
Cancer cells, especially those with high energy demands, may be particularly sensitive to a drop in ATP levels. The inhibition of Complex I also increases the AMP/ATP ratio, setting the stage for the activation of downstream energy stress pathways.
AMPK activation results in the inhibition of the mammalian target of rapamycin (mTOR) pathway, a central regulator of protein synthesis and cellular growth. mTOR inhibition reduces cell proliferation and limits tissue growth, which can slow tumor progression.

Metformin reduces circulating insulin levels, which in turn can decrease the activation of the insulin and insulin-like growth factor-1 (IGF-1) receptor pathways.

ETC Inhibitors: Drugs that directly inhibit specific ETC complexes (e.g., Complex I inhibitors like metformin or phenformin) can increase electron leakage and ROS production.(dose- and context-dependent, and not consistent)

-known as mild OXPHOS inhibitor(Complex I modulator)

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Mitochondrial Complex I (OXPHOS) inhibition Energetic stress ↑; proliferation pressure ↓ (context) Hepatic energy shift; gluconeogenesis ↓ P, R Bioenergetic modulation Metformin partially inhibits mitochondrial Complex I (OXPHOS), increasing AMP/ADP ratio and triggering downstream AMPK activation. ROS changes are dose- and context-dependent.
2 AMPK activation (LKB1/AMPK axis) Growth programs ↓ (context-dependent) Metabolic homeostasis ↑ R Energy-sensor activation AMPK activation is frequently invoked downstream of respiratory inhibition, though some hepatic effects can be AMPK-independent.
3 mTORC1 inhibition (via AMPK→TSC2/Raptor; also AMPK-independent routes reported) Protein synthesis / growth signaling ↓ (reported) Reduced anabolic signaling in liver (context) R, G Anti-anabolic signaling Mechanistically supported: AMPK regulation of TSC2 and Raptor contributes to metformin-mediated mTORC1 inhibition; AMPK-independent mTORC1 inhibition has also been described.
4 Hepatic gluconeogenesis suppression Indirect tumor support via insulin/IGF-1 lowering (systemic) Liver glucose production ↓ (core clinical effect) R, G Systemic metabolic effect Metformin reduces hepatic glucose output through multiple mechanisms (energy state shifts, cAMP pathways, and other proposed nodes).
5 Insulin / IGF-1 axis (systemic growth signaling) Mitogenic tone ↓ (context; strongest in hyperinsulinemic settings) Insulin sensitivity ↑; insulin levels ↓ (context) G Systemic growth-factor modulation Many “anti-cancer” hypotheses depend on lowering insulin/IGF-1 signaling rather than direct tumor cytotoxicity.
6 Cell-cycle & apoptosis (secondary, model-dependent) Proliferation ↓; apoptosis ↑ (reported in some models) ↔ G Conditional cytostasis Often downstream of mTORC1 suppression/energy stress; not a universal direct cytotoxin signature.
7 Inflammation signaling (NF-κB and related programs) Inflammatory pro-survival transcription ↓ (reported) Anti-inflammatory trends in metabolic disease contexts R, G Inflammation modulation Frequently reported as downstream of improved metabolic/oxidative stress tone; avoid presenting as a primary direct target.
8 Autophagy / stress adaptation Autophagy ↑ or ↓ depending on context; can affect therapy response ↔ G Adaptive stress response Autophagy findings are heterogeneous across tumor models and combinations.
9 Clinical oncology evidence (adjunct use) Observational signals exist; randomized data are mixed — — Translation constraint Epidemiology/meta-analyses suggested potential benefit in some cancers, but large randomized trials (e.g., adjuvant breast cancer MA.32) did not show broad benefit across the overall population.
10 Safety / monitoring constraints (B12, lactic acidosis risk in predisposed states) — Vitamin B12 deficiency risk with long-term use; rare lactic acidosis risk increases with renal impairment and other conditions — Clinical risk management Long-term B12 monitoring is commonly advised; prescribing requires renal function assessment due to lactic acidosis risk in predisposed settings.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid bioenergetic effects)
  • R: 30 min–3 hr (acute signaling shifts: AMPK/mTOR)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)
LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
1640- CA,  MET,    Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines
- in-vitro, Cerv, SiHa
GLS↓, NADPH↓, ROS↑, TumCD↑, AMPK↑, Hif1a↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDH↓, cMyc↓, BAX↓, cycD1/CCND1↓, PDH↓, ROS↑, Apoptosis↑, eff↑, ACLY↓, FASN↓, Bcl-2↓, Glycolysis↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 2,  

Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   AMPK↑, 1,   cMyc↓, 1,   FASN↓, 1,   GLS↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   LDH↓, 1,   NADPH↓, 1,   PDH↓, 1,   PFK↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↓, 1,   Bcl-2↓, 1,   TumCD↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT3↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  
Total Targets: 23

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:11  Target#:906  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page